138 related articles for article (PubMed ID: 34401057)
21. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
22. Biodegradable nanoparticles from prosopisylated cellulose as a platform for enhanced oral bioavailability of poorly water-soluble drugs.
Kenechukwu FC; Dias ML; Ricci-Júnior E
Carbohydr Polym; 2021 Mar; 256():117492. PubMed ID: 33483021
[TBL] [Abstract][Full Text] [Related]
23. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Yousaf AM; Mustapha O; Kim DW; Kim DS; Kim KS; Jin SG; Yong CS; Youn YS; Oh YK; Kim JO; Choi HG
Int J Nanomedicine; 2016; 11():213-21. PubMed ID: 26834471
[TBL] [Abstract][Full Text] [Related]
24. Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size.
Pi J; Liu Z; Wang H; Gu X; Wang S; Zhang B; Luan H; Zhu Z
Curr Drug Deliv; 2016; 13(8):1358-1366. PubMed ID: 26953239
[TBL] [Abstract][Full Text] [Related]
25. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
26. In silico-in vitro-in vivo studies of experimentally designed carvedilol loaded silk fibroin-casein nanoparticles using physiological based pharmacokinetic model.
Kumar S; Singh SK
Int J Biol Macromol; 2017 Mar; 96():403-420. PubMed ID: 28013012
[TBL] [Abstract][Full Text] [Related]
27. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Kumar R; Singh A; Garg N; Siril PF
Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
[TBL] [Abstract][Full Text] [Related]
28. Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion.
Zhou K; Huo M; Ma W; Mi K; Xu X; Algharib SA; Xie S; Huang L
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33922109
[TBL] [Abstract][Full Text] [Related]
29. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
30. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Low Molecular Weight Cross Linked Chitosan Nanoparticles, to Enhance the Bioavailability of 5-Flourouracil.
Sethi A; Ahmad M; Huma T; Khalid I; Ahmad I
Dose Response; 2021; 19(2):15593258211025353. PubMed ID: 34377107
[TBL] [Abstract][Full Text] [Related]
32. Palmitic Acid-Pluronic F127-Palmitic Acid Pentablock Copolymer as a Novel Nanocarrier for Oral Delivery of Glipizide.
Kamboj VK; Verma PK
Turk J Pharm Sci; 2019 Sep; 16(3):265-272. PubMed ID: 32454724
[TBL] [Abstract][Full Text] [Related]
33. Phytophospholipid Complex of Caffeic Acid: Development, In vitro Characterization, and In Vivo Investigation of Antihyperlipidemic and Hepatoprotective Action in Rats.
Mangrulkar S; Shah P; Navnage S; Mazumdar P; Chaple D
AAPS PharmSciTech; 2021 Jan; 22(1):28. PubMed ID: 33404939
[TBL] [Abstract][Full Text] [Related]
34. Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization.
Dudhipala N; Ettireddy S; Youssef AAA; Puchchakayala G
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946619
[TBL] [Abstract][Full Text] [Related]
35. Development and optimisation of 3-Acetyl-11-keto-β-boswellic acid loaded poly-lactic-co-glycolic acid-nanoparticles with enhanced oral bioavailability and in-vivo anti-inflammatory activity in rats.
Bairwa K; Jachak SM
J Pharm Pharmacol; 2015 Sep; 67(9):1188-97. PubMed ID: 25851251
[TBL] [Abstract][Full Text] [Related]
36. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
37. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
Singh H; Jindal S; Singh M; Sharma G; Kaur IP
Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
[TBL] [Abstract][Full Text] [Related]
38. Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats.
Zhang G; Zhang J
Drug Des Devel Ther; 2018; 12():2509-2518. PubMed ID: 30147298
[TBL] [Abstract][Full Text] [Related]
39. Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability.
Khan MA; Ansari MM; Arif ST; Raza A; Choi HI; Lim CW; Noh HY; Noh JS; Akram S; Nawaz HA; Ammad M; Alamro AA; Alghamdi AA; Kim JK; Zeb A
Drug Deliv; 2021 Dec; 28(1):2510-2524. PubMed ID: 34842018
[TBL] [Abstract][Full Text] [Related]
40. Preparation of ursolic acid-phospholipid complex by solvent-assisted grinding method to improve dissolution and oral bioavailability.
Wang W; Zhang W; Jiang Y; Wang X; Zhang X; Liu H; Zhang T
Pharm Dev Technol; 2020 Jan; 25(1):68-75. PubMed ID: 31544585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
